title: The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients.
abstract: Treatment with tyrosine kinase inhibitors (TKIs) has dramatically changed the life expectancy of chronic myeloid leukaemia (CML) patients. Although the impact of first-generation TKIs on quality of life (QoL) was shown in CML, the effects of new generic formulations of imatinib mesylate (IM) are unclear. We evaluated differences in QoL under treatment with first- or second-generation TKIs. Fifty-two patients diagnosed with CP-CML completed the European Organization for Research and Treatment of Cancer Quality of Life Questionaire-C30, Hospital Anxiety and Depression Scale, and General Health Questionnaire. General QoL scores were similar between groups. There was a significant difference in the frequency of diarrhoea between IM group and the group using new generic formulations of IM (P = 0.012). General QoL score tended to be higher in patients with disease duration longer than 3 years (P = 0.052). GHQ, anxiety and depression scores correlated positively with symptom scales and negatively with functional subscales.CML patients using new generic formulations of IM reported a higher frequency of diarrhoea than patients using original IM and second-generation TKIs that could result in more drug discontinuation.
authors.affiliation: Department of Hematology, Trakya University Medical Faculty, Edirne, Turkey.
authors.forename: Mehmet S
authors.initials: MS
authors.lastname: Uyanik
authors.affiliation: Department of Hematology, Trakya University Medical Faculty, Edirne, Turkey.
authors.forename: Gulsum E
authors.initials: GE
authors.lastname: Pamuk
authors.affiliation: Department of Hematology, Trakya University Medical Faculty, Edirne, Turkey.
authors.forename: Muhammet
authors.initials: M
authors.lastname: Maden
authors.affiliation: Department of Internal Medicine, Trakya University Medical Faculty, Edirne, Turkey.
authors.forename: Elif
authors.initials: E
authors.lastname: Merev
authors.affiliation: Department of Psychiatry, Edirne State Hospital, Edirne, Turkey.
authors.forename: Gokcen
authors.initials: G
authors.lastname: Cevik
authors.affiliation: Department of Psychiatry, Edirne State Hospital, Edirne, Turkey.
authors.forename: Vesile
authors.initials: V
authors.lastname: Uyanik
authors.affiliation: Department of Hematology, Trakya University Medical Faculty, Edirne, Turkey.
authors.forename: Elif G
authors.initials: EG
authors.lastname: Umit
authors.affiliation: Department of Hematology, Trakya University Medical Faculty, Edirne, Turkey.
authors.forename: Ahmet M
authors.initials: AM
authors.lastname: Demir
authors.affiliation: Department of Internal Medicine, Trakya University Medical Faculty, Edirne, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Akker
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000523:psychology; D003863:Depression / Q000523:psychology; D003967:Diarrhea / Q000139:chemically induced; D016568:Drugs, Generic / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000523:psychology; D016014:Linear Models; D060046:Maintenance Chemotherapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011788:Quality of Life; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D016568:Drugs, Generic; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate
keywords: leukaemia; quality of life